Olezarsen for Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease Management

This study is about a drug called Olezarsen (ISIS 678354), which is being tested in people with high triglyceride levels and atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is a condition where plaque builds up inside the arteries, which can lead to heart attacks or strokes. The study aims to enroll around 1475 participants. The goal of this research is to understand if Olezarsen can help manage high triglyceride levels, a type of fat found in the blood, and potentially slow down the progression of atherosclerotic cardiovascular disease. During the study, participants will receive either Olezarsen or a placebo (a substance that has no therapeutic effect) once every 4 weeks for about a year. The study is divided into three parts: a screening period, a treatment period, and a follow-up period. The main outcome of interest is the change in fasting triglyceride levels from the start of the study to week 25. Additionally, a sub-study using coronary computed tomographic angiography (CTA), a type of imaging test, will be conducted to see if lowering triglyceride levels through Olezarsen can slow down the progression of plaque buildup in the coronary arteries.